Methods: In CHARM, a Phase III study of 854 patients with moderately to severely active CD, open-label adalimumab was administered at Weeks 0 and 2 (80 mg and 40 mg, respectively). Patients were then randomized to receive blinded therapy of adalimumab 40 mg every other week (eow), adalimumab 40 mg weekly, or placebo for up to 56 weeks. Patients receiving steroids were included in the study if they had been on a stable dosage of 30 mg/day prednisone (or equivalent) for 2 weeks prior to screening. The current post-hoc subanalysis evaluated data from the intention-to-treat population of patients receiving steroids at baseline who were randomized to adalimumab and assessed for steroid-free remission at 3 years from CHARM baseline. Remission rates were calculated using nonresponder imputation (NRI) analysis. Results: In CHARM, 206 patients receiving steroids at baseline were randomized to adalimumab treatment. At 2 and 3 years after CHARM baseline, respectively, 27% and 28% of these patients were in steroid-free remission (table). 
Steroid-free remission rates through 3 years of adalimumab therapy: patients receiving steroids at baseline and randomized to adalimumab (NRI) Conclusions: Adalimumab therapy resulted in clinically meaningful rates of steroid-free remission in patients who were receiving steroids when they entered the CHARM study. Steroidfree remission rates were observed after 3 years of adalimumab treatment.
Reference ( Conclusions: Adalimumab therapy led to clinically meaningful rates of complete fistula healing at Week 12, which were sustained through Week 20. Adalimumab was effective in anti-TNF-naive patients and patients who had failed therapy with infliximab. Adalimumab was well-tolerated, with safety consistent with prior reports in CD. Aim: to assess efficacy of mesenchymal stem cells in patients with Ulcerative Colitis and Crohn's disease for clinical and endoscopic improvement. Materials and Methods: 16 patients with ulcerative colitis (UC), 7 patients with Crohn's disease (CD) were included in the study. Minimal age of patients was 19 yrs, maximal age was 60 yrs. The duration of the diseases varied from 6 months to 10 years. 14 patients had continuous course of the diseases. Physical examination, common and biochemical blood analysis, rectoscopy, colonoscopy for all patient were performed before and 2 months past treatment. Disease activity was estimated using clinical (CAI) Rachmilevitz and endoscopic (EAI) Rachmilevitz activity index in patient with UC, and activity index Best (CDAI) in patient with CD. Mesenchymal stem cells (MCSs) were obtained from healthy donors by iliac crest puncture. Punctates were processed to final drug form containing 150 200 x10 6 MSCs, which introduced to all patients by intravenous injection. Accompanying treatment depended on activity of the diseases: aminosalicylates declined to 2.0 g per day, dose of steroids were halved, cytostatic agents were taken off at once. 
